Australian blood plasma fractionation company Aegros is pleased to announce the appointment of Dr Leon Rozen as Chief Medical Officer.

With more than 25 years’ experience in global medical affairs and medical communications, Dr Rozen has shown medical leadership of launches across therapeutic areas at global, regional and affiliate levels, while interacting with clinical and commercial stakeholders as a medical science liaison.

Dr Rozen has had a number of roles in the industry including as Medical Director of the Pharmaceutical Division of CSL and Vice President of Global Medical Affairs and Immunology at Baxter in Chicago. Most recently he was Medical Director ANZ for Ipsen, a global pharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience.

Aegros’ Founding Executive Chairman Professor Hari Nair said Dr Rozen’s appointment strengthens the company’s position as an up-and-coming leader in the blood fractionation industry.

“We are delighted to have Leon join our expanding team, and his experience across a number of world leading pharmaceutical, immunology, and plasma companies will be invaluable to us here at Aegros.

“We are confident his medical leadership and medical communication skills will help to further bolster the expertise within the company as we seek to finalise our CHAT trial for the hyperimmune against Covid-19 and then register our product with the ARTG.”

Dr Rozen, a trained haematologist, holds a Bachelor of Medical Science and a Doctor of Medicine from Monash University, and is a fellow of both the Royal College of Pathologists of Australasia, and the Royal College of Medical Administrators.